Hepatitis C Virus NS3/4A Protease Inhibitor class drugs
1 result
Mavyret (glecaprevir and pibrentasvir)
(Glecaprevir and Pibrentasvir)AbbVie Inc.
Usage: MAVYRET is indicated for treating chronic hepatitis C virus (HCV) genotypes 1-6 in patients aged 3 and older, including those with or without cirrhosis. It is also for patients with HCV genotype 1 who have previously received treatment with an NS5A inhibitor or an NS3/4A protease inhibitor.